ASTRAZENECA PLC
AZNNYSEHealthcare · Pharmaceutical Preparations · X0 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
FDA-approved drugs
openFDA · most recent- TRUQAPNov 16, 2023
- SYMBICORT AEROSPHEREApr 28, 2023
- AIRSUPRAJan 10, 2023
- KOSELUGOApr 10, 2020
- LOKELMAMay 18, 2018
- CALQUENCEOct 31, 2017
- BEVESPI AEROSPHEREApr 25, 2016
- TAGRISSONov 13, 2015
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2009-07-30Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
- Phase 3Active Not Recruitingreadout ~2016-06-07Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
- Phase 2Active Not Recruitingreadout ~2021-01-11Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
- Phase 3Active Not Recruitingreadout ~2022-10-27Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
- Phase 3Active Not Recruitingreadout ~2024-01-03Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
- Phase 3Active Not Recruitingreadout ~2024-01-15Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Phase 2Active Not Recruitingreadout ~2024-07-29A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
- Phase 2Active Not Recruitingreadout ~2024-10-07Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.2M | 1.2 | +18.1% |
| Apr 30, 2026 | 1.8M | 1.0 | +5.2% |
| Apr 15, 2026 | 1.7M | 1.0 | +8.0% |
| Mar 31, 2026 | 1.6M | 1.0 | -18.4% |
| Mar 13, 2026 | 2.0M | 1.0 | -17.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Recent SEC filings
All filings ↗- 6-KADMISSION OF FURTHER SECURITIES TO TRADINGJun 1, 2026
- 6-KTOTAL VOTING RIGHTSJun 1, 2026
- 6-KIMFINZI APPROVED IN US FOR EARLY BLADDER CANCERMay 29, 2026
- 25-NSEMay 28, 2026
- 6-KUS FDA DECISION DATE ON CAMIZESTRANT EXTENDEDMay 27, 2026
- 6-KDATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BCMay 26, 2026
- 6-KENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURSMay 26, 2026
- 6-KCAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EUMay 26, 2026
- 4OWNERSHIP DOCUMENTMay 22, 2026
- 6-KDIRECTOR/PDMR SHAREHOLDINGMay 18, 2026
- 6-KBAXFENDY APPROVED IN THE US FOR HYPERTENSIONMay 18, 2026
- 6-KENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGSMay 18, 2026
- 6-KIMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCERMay 14, 2026
- 4OWNERSHIP DOCUMENTMay 8, 2026
- 6-KTOTAL VOTING RIGHTS AND ADMISSION OF SHARESMay 1, 2026
Event-driven situations (5)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.